Interpreting Cancer Biomarker Testing - When Is Additional Testing Needed? (CME)

Precision Medicine for Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Interpreting Cancer Biomarker Testing - When Is Additional Testing Needed?, participants will practice interpreting results from cancer biomarker tests, which test for dozens or hundreds of genomic variants and other biomarkers that may be driving cancer growth and may be targetable with treatment. Learn about when additional testing is indicated for further evaluation of genome-informed therapy, using the five parts of this module: an animated video providing overview information; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

To claim credit, follow the steps in the learning path.

CME Information and Disclosures

Activity Overview
Precision Medicine for Your Practice: Interpreting Cancer Biomarker Testing - When Is Additional Testing Needed? (CME)

Publication Date: January 11, 2024
Expiration Date: January 11, 2027

Learning Objectives
Upon completion of this educational activity, the learner will be able to:

• Identify limitations of different test methodologies 
• Identify when additional testing is indicated to further evaluate for genome-informed therapy

Target Audience
This activity is designed to meet the educational needs of practicing physicians who provide oncology care.

Accreditation Statement
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 4 out of 5 questions correctly and 4) complete the evaluation.  

Credit Designation Statement
The American Medical Association designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Multimedia Contributors

• Emily Edelman, MS, CGC, Director, Clinical Education, The Jackson Laboratory
• Therese Ingram, MA, Associate Director and Senior Instructional Designer/Technologist, Clinical Education, The Jackson Laboratory
• Kalisi Logan, MS, CGC, Clinical Genomic Educator, Clinical Education, The Jackson Laboratory
• Laura Nicholson, MD, PhD, Director of Research, Graduate Medical Education (GME), Scripps HealthKate Reed, MPH, ScM, CGC, Director, Precision Oncology Education, Clinical Education, The Jackson Laboratory
• Linda Steinmark, MS, CGC, Project Manager, Clinical Education, The Jackson Laboratory

Disclosure Statement
Unless noted, all individuals in control of content reported no relevant financial relationships.

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program:

Kalisi Logan, MS, CGC, advisor for Igentify. Ms. Logan's contributions were peer reviewed by non-conflicted team members and modified as needed according to the results for the review to remove any identified commercial bias. 

References

Anderson, E., Hinton, A., Lary, C., et al. (2021). Community oncologists' perceptions and utilization of large-panel genomic tumor testing. BMC Cancer, 21(1):1273.

Aziza, S., Pezo, R., Jerzak, K., et al. (2021). Patients’ and Oncologists’ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review. Oncologist, 26(8):e1359-e1371.

Buckenmaier, S., Mollica, M., Freedman, A., et al. (2021). Information Sources Used by Oncologists to Understand Multi-marker Tumor Panel Tests for Cancer Patients. J Cancer Educ, 36(5):1105-1114.

de Moor, J., Gray, S., Mitchell, S., et al. (2020). Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice. JCP Precis Oncol, 4(4):620-631.

Doig, K., Fellowes, A. & Fox, S. (2023). Homologous Recombination Repair Deficiency: An Overview for Pathologists. Mod Pathol, 36(3):100049.

Freedman, A., Klabunde, C., Wiant, K. et al. (2018). Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCP Precis Oncol, 2:PO.18.00169.

Fusco, M., Saeed-Vafa, D., Carballido, E., et al. (2021). Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. JCO Precision Oncology, 5: 65-74.

Hall, M., D’Avanzo, P., Chertock, Y., et al. (2021). Oncologists' Perceptions of Tumor Genomic Profiling and the Communication of Test Results and Risks. Public Health Genomics, 24(5-6): 304-309.

Lazure, P., Parikh, A., Ready, N., et al. (2022). Challenges associated with the integration of immuno-oncology agents in clinical practice. BMC Med Educ, 22(1):781.

Luchini C., Paolino G., Mattiolo P., et al. (2020). KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res 39(1):227.

Mandelker, D., Donoghue, M., Talukdar, S., et al. (2019). Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol, 30(8), 1221-1231.

Manea, C., Badiu, D., Ploscaru, I., et al. (2022). A review of NTRK fusions in cancer. Ann Med Surg (Lond),  79: 103893. 

National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, v2.2023. Retrieved 6/29/23.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers, v2.2023. Retrieved 6/29/23.

Shah M., Hogstetter W., Kennedy E. et al. (2021). Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update. JCO 39(28): 3182-3184.

Tomlins S., Hovelson D., Suga J. et al. (2021). Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precis Oncol. 19(5):PO.20.00472. 

Hardware/Software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.

Disclaimer 
All information in Precision Medicine for Your Practice is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Precision Medicine for Your Practice. Reliance on any information in Precision Medicine for Your Practice is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Precision Medicine for Your Practice.